

# Johannes Wohlrab

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4307863/publications.pdf>

Version: 2024-02-01

82  
papers

2,012  
citations

257101

24  
h-index

288905

40  
g-index

116  
all docs

116  
docs citations

116  
times ranked

2147  
citing authors

#	ARTICLE	IF	CITATIONS
1	Skin Diseases Associated with the Depletion of Stratum Corneum Lipids and Stratum Corneum Lipid Substitution Therapy. <i>Skin Pharmacology and Physiology</i> , 2015, 28, 42-55.	1.1	153
2	Dermal and transdermal delivery of pharmaceutically relevant macromolecules. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 119, 235-242.	2.0	109
3	Ceramide profiles of the uninvolved skin in atopic dermatitis and psoriasis are comparable to those of healthy skin. <i>Archives of Dermatological Research</i> , 2005, 296, 514-521.	1.1	104
4	Niacinamide - Mechanisms of Action and Its Topical Use in Dermatology. <i>Skin Pharmacology and Physiology</i> , 2014, 27, 311-315.	1.1	91
5	Profiling of human stratum corneum ceramides by means of normal phase LC/APCI-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2005, 383, 632-637.	1.9	76
6	Dermal targeting of tacrolimus using colloidal carrier systems. <i>International Journal of Pharmaceutics</i> , 2011, 404, 159-168.	2.6	67
7	Diagnostic impact and sensitivity of skin biopsies in Sneddon's syndrome. A report of 15 cases. <i>British Journal of Dermatology</i> , 2001, 145, 285-288.	1.4	61
8	Potential Applications of Phyto-Derived Ceramides in Improving Epidermal Barrier Function. <i>Skin Pharmacology and Physiology</i> , 2017, 30, 115-138.	1.1	58
9	Clinical Applications of Hyaluronidase. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1148, 255-277.	0.8	58
10	Noninvasive characterization of human stratum corneum of undiseased skin of patients with atopic dermatitis and psoriasis as studied by Fourier transform Raman spectroscopy. <i>Biopolymers</i> , 2001, 62, 141-146.	1.2	52
11	Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 674-689.	0.4	50
12	Persistent erythema and edema of the midthird and upper aspect of the face (morbus morbihan): Evidence of hidden immunologic contact urticaria and impaired lymphatic drainage. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 595-602.	0.6	46
13	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 91-98.	1.1	44
14	Controlled nail delivery of a novel lipophilic antifungal agent using various modern drug carrier systems as well as in vitro and ex vivo model systems. <i>Journal of Controlled Release</i> , 2014, 180, 60-70.	4.8	39
15	Polyglycerol fatty acid ester surfactant-based microemulsions for targeted delivery of ceramide AP into the stratum corneum: Formulation, characterisation, in vitro release and penetration investigation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 82, 139-150.	2.0	37
16	Controlled penetration of ceramides into and across the stratum corneum using various types of microemulsions and formulation associated toxicity studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 244-250.	2.0	36
17	Lecithin-Based Microemulsions for Targeted Delivery of Ceramide AP into the Stratum Corneum: Formulation, Characterizations, and In Vitro Release and Penetration Studies. <i>Pharmaceutical Research</i> , 2013, 30, 538-551.	1.7	34
18	Dermal and transdermal targeting of dihydroavenanthramide D using enhancer molecules and novel microemulsions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 552-560.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Human dermal pericytes express 3G5 ganglioside - A new approach for microvessel histology in the skin. <i>Journal of Cutaneous Pathology</i> , 2001, 28, 206-210.	0.7	29
20	Antiseptic Efficacy of a Low-Dosed Topical Triclosan/Chlorhexidine Combination Therapy in Atopic Dermatitis. <i>Skin Pharmacology and Physiology</i> , 2007, 20, 71-76.	1.1	28
21	Interaction of Epicutaneously Applied Lipids with Stratum Corneum Depends on the Presence of either Emulsifiers or Hydrogenated Phosphatidylcholine. <i>Skin Pharmacology and Physiology</i> , 2010, 23, 298-305.	1.1	28
22	Clinical Trial for Safety Evaluation of Hyaluronidase as Diffusion Enhancing Adjuvant for Infiltration Analgesia of Skin with Lidocaine. <i>Dermatologic Surgery</i> , 2012, 38, 91-96.	0.4	27
23	Delivery of oat-derived phytoceramides into the stratum corneum of the skin using nanocarriers: Formulation, characterization and in vitro and ex-vivo penetration studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 127, 260-269.	2.0	27
24	Modulation of Dihydroavenanthramide D release and skin penetration by 1,2-alkanediols. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 239-247.	2.0	26
25	Comparison of noncross-linked and cross-linked hyaluronic acid with regard to efficacy of the proliferative activity of cutaneous fibroblasts and keratinocytes <i>in vitro</i> . <i>Journal of Cosmetic Dermatology</i> , 2013, 12, 36-40.	0.8	23
26	Cutis Marmorata Telangiectatica Congenita: Laser Doppler Fluxmetry Evidence for a Functional Nervous Defect. <i>Pediatric Dermatology</i> , 2001, 18, 110-113.	0.5	21
27	Dermal Peptide Delivery Using Enhancer Molecules and Colloidal Carrier Systems – Part I: Carnosine. <i>Skin Pharmacology and Physiology</i> , 2012, 25, 281-287.	1.1	21
28	Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part II: Tetrapeptide PKEK. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 124, 28-33.	2.0	21
29	Submammary granular parakeratosis: an acquired punctate hyperkeratosis of exogenous origin. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 813-4.	0.6	21
30	Früherkennung der Komorbidität bei Psoriasis: Konsensusempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 674-690.	0.4	19
31	Cutaneous Drug Delivery of Capsaicin after in vitro Administration of the 8% Capsaicin Dermal Patch System. <i>Skin Pharmacology and Physiology</i> , 2015, 28, 65-74.	1.1	19
32	Topical preparations and their use in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1061-1070.	0.4	19
33	Dermal delivery of desmopressin acetate using colloidal carrier systems. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 423-427.	1.2	18
34	S2k guidelines for the use of topical preparations on the skin. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 376-392.	0.4	18
35	Pathomechanism of dupilumab-associated inflammatory eye symptoms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e435-e436.	1.3	18
36	Scabies: epidemiology, diagnosis, and treatment. <i>Deutsches Ärzteblatt International</i> , 2021, 24, 100-104.	0.6	18

#	ARTICLE	IF	CITATIONS
37	Skin tolerability of transdermal patches. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 939-948.	2.4	17
38	Efficacy Study of Hyaluronidase as a Diffusion Promoter for Lidocaine in Infiltration Analgesia of Skin. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 771e-772e.	0.7	17
39	Use of Hyaluronidase for Pharmacokinetic Increase in Bioavailability of Intracutaneously Applied Substances. <i>Skin Pharmacology and Physiology</i> , 2014, 27, 276-282.	1.1	17
40	Lipids in the Skin and pH. <i>Current Problems in Dermatology</i> , 2018, 54, 64-70.	0.8	16
41	Skin diseases in diabetes mellitus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 37-53.	0.4	15
42	The Influence of L-Arginine on the Regulation of Epidermal Arginase. <i>Skin Pharmacology and Physiology</i> , 2002, 15, 44-54.	1.1	14
43	Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part III: Tetrapeptide GEKG. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 124, 137-144.	1.9	14
44	Pharmacokinetic characteristics of therapeutic antibodies. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 530-534.	0.4	13
45	Methotrexate for topical application in an extemporaneous preparation. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 891-901.	0.4	13
46	S2 Leitlinie zum Gebrauch von Präparationen zur lokalen Anwendung auf der Haut (Topika). <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 376-392.	0.4	12
47	Characterization of cationic amino acid transporters (hCATs) 1 and 2 in human skin. <i>Histochemistry and Cell Biology</i> , 2008, 129, 321-329.	0.8	11
48	Importance of microRNAs in Skin Oncogenesis and Their Suitability as Agents and Targets for Topical Therapy. <i>Skin Pharmacology and Physiology</i> , 2020, 33, 270-279.	1.1	11
49	Controlled Penetration of a Novel Dimeric Ceramide into and across the Stratum Corneum Using Microemulsions and Various Types of Semisolid Formulations. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 130-134.	1.1	10
50	Pharmakokinetische Besonderheiten von therapeutischen Antikörpern. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 530-534.	0.4	9
51	Development and validation of LC/APCI-MS method for the quantification of oat ceramides in skin permeation studies. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 4775-4785.	1.9	9
52	Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 115.	1.0	8
53	Methotrexat für die topische Applikation in magistraler Rezeptur. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 891-902.	0.4	8
54	Skin diseases in intensive care medicine. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 108-115.	0.4	7

#	ARTICLE	IF	CITATIONS
55	Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch. <i>Skin Pharmacology and Physiology</i> , 2022, 35, 94-101.	1.1	7
56	Acute Effect of a Dried Ethanol-Water Extract of Garlic on the Microhaemovascular System of the Skin. <i>Arzneimittelforschung</i> , 2000, 50, 606-612.	0.5	6
57	Quantification of Tacrolimus in Human Skin Samples and Ointment by LC-MS. <i>Chromatographia</i> , 2009, 70, 581-584.	0.7	6
58	Topika und deren Einsatz in der Dermatologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1061-1071.	0.4	6
59	Effects of L-Ornithine on Metabolic Processes of the Urea Cycle in Human Keratinocytes. <i>Skin Pharmacology and Physiology</i> , 2004, 17, 283-288.	1.1	4
60	Contact allergies to topical antibiotic applications. <i>Allergologie Select</i> , 2022, 6, 18-26.	1.6	4
61	The Importance of Cationic Amino Acid Transporter Expression in Human Skin. <i>Journal of Investigative Dermatology</i> , 2003, 121, 1552-1553.	0.3	3
62	Anti-inflammatory lipid components for topical use. <i>Journal of Cosmetic Dermatology</i> , 2003, 2, 103-104.	0.8	3
63	Comparison Between Fluorescence and Pulsed Integrated Electrochemical Detectors for the Determination of Taurine in Human Skin, Urine and Plasma by CE. <i>Chromatographia</i> , 2008, 67, 813-817.	0.7	3
64	Hydrocortisone Aceponate Activity and Benefit/Risk Ratio in Relation to Reference Topical Glucocorticoids. <i>Skin Pharmacology and Physiology</i> , 2010, 23, 177-182.	1.1	3
65	The use of local concentrated heat versus topical acyclovir for a herpes labialis outbreak: results of a pilot study under real life conditions. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2013, 6, 263.	0.8	3
66	Ex vivo Cutaneous Bioavailability of Topical Mometasone Furoate in an O/W Preparation. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 273-279.	1.1	3
67	Influence of keratolytics on cutaneous pharmacokinetics of glucocorticoids. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 554-561.	0.4	3
68	The NO release test as a functional reference standard for laser Doppler fluxmetry in cutaneous microangiology. <i>Skin Research and Technology</i> , 2001, 7, 172-175.	0.8	2
69	Iloprost in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 56-63.	0.4	2
70	Anti-inflammatory topical medication – new developments in the treatment of atopic dermatitis. <i>Allergologie Select</i> , 2021, 5, 260-264.	1.6	2
71	An update on the adalimumab biosimilar landscape following approval of the first high-concentration biosimilar. <i>Immunotherapy</i> , 2022, 14, 235-252.	1.0	2
72	Preclinical and clinical characterization of the cutaneous bioavailability of the hydrophilic phase of a water-in-oil emulsion. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 698-705.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Dapson für die topische Therapie in magistralen Rezepturen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 34-41.	0.4	1
74	Dapsone for topical use in extemporaneous preparations. JDDG - Journal of the German Society of Dermatology, 2018, 16, 34-40.	0.4	1
75	Sterile transient neonatal pustulosis "overlap between transient neonatal pustular melanosis and erythema toxicum neonatorum. JDDG - Journal of the German Society of Dermatology, 2019, 17, 731-732.	0.4	1
76	Expression and activity of IL-17 receptor subunits in human cutaneous cells as targets for anti-IL-17 therapeutic antibodies. Biomedicine and Pharmacotherapy, 2022, 146, 112569.	2.5	1
77	NMDA receptors influence the intracellular calcium concentration and the expression of differentiation markers in HaCaT cells. Experimental Dermatology, 2008, 13, 579-579.	1.4	0
78	Präklinische und klinische Validierung der kutanen Bioverfügbarkeit der hydrophilen Phase einer W/O-Emulsion. JDDG - Journal of the German Society of Dermatology, 2016, 14, 698-706.	0.4	0
79	Kosmetika "medizinische und rechtliche Grundlagen. , 2004, , 47-83.		0
80	Diabetische Folgeerkrankungen. , 2014, , 239-296.		0
81	Hautpflege. , 2020, , 349-350.		0
82	Kosmetische Forschung und Bewertung von Kosmetika. , 0, , 65-84.		0